Cargando…
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
SIMPLICITY (NCT01244750) is an observational study exploring tyrosine kinase inhibitor (TKI) use and management patterns in patients with chronic phase‐chronic myeloid leukemia in the US and Europe in routine clinical practice. Herein we describe interruptions, discontinuations and switching of TKI...
Autores principales: | Hehlmann, Rüdiger, Cortes, Jorge E., Zyczynski, Teresa, Gambacorti‐Passerini, Carlo, Goldberg, Stuart L., Mauro, Michael J., Michallet, Mauricette, Simonsson, Bengt, Williams, Loretta A., Gajavelli, Srikanth, DeGutis, Irene, Sen, Ginny P., Paquette, Ron L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587733/ https://www.ncbi.nlm.nih.gov/pubmed/30290003 http://dx.doi.org/10.1002/ajh.25306 |
Ejemplares similares
-
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2020) -
First‐line treatment selection and early monitoring patterns in chronic phase‐chronic myeloid leukemia in routine clinical practice: SIMPLICITY
por: Goldberg, Stuart L., et al.
Publicado: (2017) -
Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population
por: Abruzzese, Elisabetta, et al.
Publicado: (2019) -
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022) -
Chronic Myeloid Leukemia in 2020
por: Hehlmann, Rüdiger
Publicado: (2020)